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, that "guidelines which recommend their routine use to prevent death after hip replacement are not justified". We believe that the existing published evidence, including the estimated low death rate pointed out by Murray et al, 1 justifies the use of some type of prophylaxis for patients undergoing THR.
The reasoning for the recommendation by Murray et al 1 that prophylaxis is not necessary can be summarised as follows:
1) The present use of pharmacological treatment is based on an earlier assumption that death due to pulmonary embolism (PE) is fairly common (1% to 2%), while in reality the death rate is probably no more than 1 to 3 per 1000. Thus, any possible benefit from pharmacological prophylactic treatment is very small.
2) The results from earlier randomised studies which show a significant reduction in the surrogate variable, venographic-positive DVT, do not necessarily imply that there would be a subsequent reduction in the overall death rate.
3) If prophylactic treatment results in an increased death rate from complications, other than PE, of 0.05% or more, the use of prophylactic treatment may actually be harmful.
4) Since there is no firm statistical conclusion as to the type of prophylaxis which should be used, or even whether any such treatment is necessary, any guidelines as to its routine use are not justified.
After There are currently no randomised studies of adequate sample size comparing a warfarin-treated with a non-treated group. Do earlier studies demonstrating a reduction in the rates of DVT prove that a reduction in death rate also follows? Clearly, the answer to the above question is 'no'. Treatment which affects surrogate variables may not necessarily lead to an equivalent effect on the outcome of interest. These randomised studies do lend weight to the results of the treatment discussed above, and help to provide statistical evidence of a substantial reduction in death from PE when chemical prophylaxis is used. Does prophylactic treatment with warfarin result in an increased risk of death due to other causes? Murray et al 1 suggest that any possible benefit of prophylactic treatment would easily be offset by an increased risk of death due to other causes. This suggestion is not borne out in the study by Fender et al, 3 in which the overall death rate for untreated patients was 1.05% compared with 0.82% for those receiving various prophylactic measures. The estimated death rates for patients treated with warfarin at UCLA v untreated patients for causes other than PE based on the analysis by Murray et al, 1 are very similar (0.24% v 0.21%). This suggested increased possible death rate of 0.03% for causes other than PE does not offset the suggested benefit of the prophylaxis of 0.14% discussed earlier. Thus, even if we presume a small increased death rate due to other causes, we still have a net reduction in the death rate of 0.11%. Is treating all patients cost-effective? The cost of the lowdose warfarin protocol is only about $US300.00 (£195.00) per operation. Given an estimated average cost of about $US20 000 (£13 000.00) for a THR, this represents a trivial additional amount when considering the possibility of saving one to two lives per 1000 operations. Thus, a reasonable decision concerning cost benefit may be based on an estimated cost of about $US300 000 (£194 800.00) medical dollars per one to two lives saved ($US300 (£195.00) times 1000 operations). Conclusion. Unlike Murray et al, 1 we find the statistical evidence that the use of a low-dose warfarin protocol results in a substantial reduction in the death rate as a result of PE, to be convincing. In addition, since the overall death rate due to other causes appears to be very similar to that for untreated patients, and since the number of THRs carried out worldwide is large, the small benefit from the use of chemical prophylaxis does result in a potential worldwide saving of over 600 lives, annually. In view of the small additional cost of providing this benefit, we conclude that guidelines which recommend the routine use of chemical prophylaxis to prevent death after hip replacement are justified.
Patients should have the option of management with prophylaxis. While the issue of what type of treatment works best is still open to question, based on our review of the statistical evidence to date we cannot consider discontinuing the regime with warfarin which we currently use.
